A Prospective, Double-blind, Randomized, and Controlled Clinical Trial to Compare the Effectiveness of Intravenous Bezlotoxumab (10 mg/kg) Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant Clostridioides Difficile Requiring Surgical Intervention.
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Bezlotoxumab (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 26 Aug 2019 Status changed from not yet recruiting to recruiting.
- 11 Mar 2019 Planned initiation date changed from 1 Jan 2019 to 1 Apr 2019.
- 04 Dec 2018 New trial record